101 results about "Sedative/hypnotic" patented technology

An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug propofol, that is pharmaceutically stable and demonstrates a reduced incidence of pain upon injection. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL® cyclodextrin (sulfobutyl ether β-cyclodextrin) to form a true aqueous solution and not a suspension. This formulation minimizes the allergic response and microbial contamination issues typically associated with propofol parenteral formulations. The present formulation may also reduce pain on injection as compared to the known emulsion type propofol formulations. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.

The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising; non-stretched melt extruded particulates comprising a drug selected from an opioid agonist, a tranquilizer, a CNS depressant, a CNS stimulant or a sedative hypnotic; and a matrix; wherein said melt extruded particulates are present as a discontinuous phase in said matrix.

The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.

The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.

The invention relates to a making method of cordyceps militaris mushroom residue biscuits. The making method includes the steps that rice or wheat cordyceps militaris mushroom residues with cordyceps militaris fruiting bodies harvested are collected, dried, crushed conventionally, puffed through a screw machine, and superfinely crushed to be in the range from 300 meshes to 2000 meshes, and then cordyceps militaris mushroom residue super-fine powder is acquired; protein sugar, baking powder and salt are dissolved in vegetable oil, self-raising flour and the cordyceps militaris mushroom residue super-fine powder are mixed, sieved and added, and soft dough is formed through kneading; a patch of dough is taken, kneaded into a round shape and slightly flattened, and biscuit blanks are made; the biscuit blanks are placed in a baking tray, placed in an electric oven to be baked, and then cooled, and therefore the cordyceps militaris mushroom residue biscuits are acquired and packaged. The puffed and superfinely-crushed cordyceps militaris mushroom residues exist in raw materials of the biscuits, and the biscuits have the antibiosis effect, the anti-cancer effect, the nourishing effect, the immune adjustment effect, the sedative-hypnotic effect and the like; the biscuits are easily absorbed by the human body and can supplement nutrients and energy which are needed by the human body; the protein sugar serves as a sweetening agent, and the biscuits are suitable for being eaten by hyperglycemia patients, diabetes patients and obese patients; the biscuits have edible safety; waste materials are not generated, and the environment is not polluted.

Controlled-release formulations providing a “pulsed” plasma profile of a sedative-hypnotic compounds having a particularly short half-life are provided. The formulation contains a sedative-hypnotic compound or precursor thereof that is metabolized to generate a sedative-hypnotic compound in vivo, wherein the compound has a mean plasma half life ranging from 0.1 to 2 hours; and at least one release retardant such that, following administration of the formulation to a patient, the patient has specified pulsed plasma profile for the sedative-hypnotic compound as disclosed herein. In a preferred embodiment, the sedative-hypnotic compound is NBI-34060.

The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.

The invention relates to the application of Albizia chinensis (Osbeck) Merr in the preparation of calming hypnotic medicine, an extract of the Albizia chinensis (Osbeck) Merr, a preparation method of the extract, and a medicine combination containing the extract. The stem skin of the Albizia chinensis (Osbeck) Merr is dried, crushed, extracted, concentrated and purified, so as to obtain the extract with the calming hypnotic function. Effective components include catechin compounds. Pharmacological tests show that the extract has the characteristics of low effective dose, quick medicinal effect exerting, obvious curative effect, good safety and high reliability.

The present invention provides novel pharmaceutical formulations of a substituted phenylacetic acid ester compound, which is useful as a short-acting sedative hypnotic agent for anesthesia and sedation. The pharmaceutical formulations are oil-in-water emulsions suitable for administration by injection. The invention further provides processes for the preparation of the formulation and the use of the formulation in medical treatment of a mammal.

The invention relates to a method for simultaneous determination of the contents of 6 kinds of sedative-hypnotic drugs in serum by a UHPLC-CAD combined technology, wherein the 6 kinds of sedative-hypnotic drugs are diazepam, lorazepam, alprazolam, estazolam, clonazepam and zolpidem tartrate. The method is characterized by including the following steps: 1) reference substance preparation, 2) internal standard solution preparation, 3) sample solution preparation, 4) mobile phase solution preparation, 5) chromatographic condition setting, 6) electrospray detector condition optimization, 7) sample determination, 8) gradient-concentration reference substance solution preparation, 9) standard curve preparation, and 10) data calculation and analysis. The method is advanced, has good clinical application prospects and effects, can rationally use drugs for clinic, increases drug curative effects, lowers toxic and side effects and drug costs, and plays a positive role.

The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-IV, VI-XI, XV-XVIII and XX-XXI and a pharmaceutically-acceptable carrier.

The invention discloses an N*-substituted adenosine derivative, a preparation method, a medicine composition and application thereof, in particular relates to an N6-substituted adenosine derivative shown as the general formula (I), two preparation methods of the derivative, a medicine composition using the derivative as effective components, and application of the derivative for preparing medicines and health care products for sedative-hypnotic, anticonvulsion, anti-epileptic, and anti-Parkinson's disease and anti-stupid. The formula (I) is shown in the description.

Polymorph Form III of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide, and use thereof as a sedative-hypnotic, anxiolytic, anticonvulsant, and / or skeletal muscle relaxant agent. Related compositions and methods are also disclosed, particularly with regard to treatment of insomnia.

The invention discloses N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazole-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide (compound ( 1)), and their use as sedative-hypnotics, anxiolytics, anticonvulsants and skeletal muscle relaxants. At the same time, methods for preparing the substance and related compositions are also disclosed, especially for the treatment of insomnia. And provides the exceptional physical and thermal stability possessed by the Form I polymorph. Type II polymorphs are also contemplated.

The invention relates to cynanchum otophyllum aglycone and medical application of an extractive containing the same, in particular to a cynanchum otophyllum extract of cynanchum otophyllum aglycone and application of cynanchum otophyllum aglycone in preparing medicines or healthy products, the medicines or the healthy products are used for tested persons to treat and / or prevent diseases or symptoms related to sleeping dysfunctions, insomnias and short sleeping time or calm and / or hypnotize or generate the effect of reducing spontaneous activities or central inhibitions. The invention also relates to a cynanchum otophyllum extractive. In the invention, the cynanchum otophyllum extractive and the cynanchum otophyllum aglycone both have calming and hypnotizing pharmacological activities, andcan be both used for preventing or treating the diseases related to calming and hypnotizing, and especially for preventing and treating the sleep dysfunction diseases caused by various factors.

The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.

The present invention relates to a preparation method of lavender sedative-hypnotic summer sleeping mat, including: (1) preparation of microcapsule lavender: (a) preparation of oil-in-water emulsion, (b) coating, (c) curing; (2) confecting a sedative-hypnotic treating agent by 110-150g / L of microcapsule lavender and 30-40g / L of adhesive; (3) spraying or brushing the sedative-hypnotic treating agent on summer sleeping mat products; (4) drying at 80-95 DEG C. The summer sleeping mat produced by the method can psychologically stabilize emotion, purify and pacificate the spirit, alleviate the sense of anger and exhaustion; in pharmacology, it has efficacy of stabilizing nerve, treating insomnia and promoting blood circulation.

The invention discloses a compound gardenia oil soft capsule and a method for preparing the same. The gardenia oil soft capsule is used for treating insomnia and consists of a content and rubber sheet, wherein the content consists of clear spina date seed oil, clear semen boitae oil and clear gardenia oil according to a mass ratio of 3:2-3:1-1.5, and the rubber sheet consists of a rubber material, humectant, water and antiseptic according to a mass ratio of 10:4-6:7-14:0.005. The clear spina date seed oil, the clear semen boitae oil and the clear gardenia oil are mixed uniformly to form the content; the water is heated and added sequentially with the humectant, the antiseptic and the rubber material to form a gum-solution; the content and the gum-solution are pressed by the prior pressing method so as to be formed; and after post treatment, the compound gardenia oil soft capsule is obtained. The compound gardenia oil soft capsule is reasonable in formula, has a sedative-hypnotic function which can be enhanced by long drug application time, is free from tolerance and suitable to be used for treating insomnia, and can relieve physical fatigue.

The invention relates to the field of medicine and discloses a Murraya paniculata leaf, a Murraya paniculata leaf extractive and new biological activity of part of a flavonoid mono compound extracted from Murraya paniculata leaves, namely discloses a Murraya paniculata leaf, a Murraya paniculata leaf extractive and the use of part of a flavonoid mono compound extracted from Murraya paniculata leaves in preparation of sedative and hypnotic drugs, anxiolytic drugs, anticonvulsive drugs or antimanic drugs, in particular to the use in preparation of sedative and hypnotic drugs.

The present invention relates to a valerian oil liquid hard capsule and its preparation method. Said capsule preparation is composed of hard capsule shell and liquid materials of valerian oil or valerian extract as main component. Said capsule preparation has the obvious effects of sedative-hypnotic, reducing bloedlipid, reducing blood pressure, improving myocardial microcirculation, resisting bacteria, resisting virus, resisting tumor and resisting fatigue, etc.

The invention provides pharmaceutical compositions comprising a phenylacetic acid ester compound useful for inducing or maintaining general anesthesia or sedation in mammals, methods for preparing such compositions, and methods for inducing or maintaining anesthesia or sedation using such compositions.

The invention belongs to the fields of medicine and chemistry, and provides a substituted phenyl acetate compound with the structure shown by formula (I), which has short-acting sedative-hypnotic effect so as to be used for preparing anesthetic and sedative. The experiments prove that the substituted phenyl acetate compound has the anesthetic activity stronger than that of propanidid, and has the action time and the recovery time which are shorter and more foreseeable than those of propofol, thus having the characteristics of being high in anesthetic effect and medicine effect, low in toxic and side effects and the like.

The invention relates to an alkaloid compound extracted and prepared from a cat bean and a valid target, wherein, the cat bean is used as a raw material, the valid target is obtained through crushing, solvent extraction, separation and purification by resin or silica gel column chromatography and other methods, and the compound, 1, 2-dihydro-3-guanido-6-hydroxymethyl-1-methylpyrazine-2-ketone, namely cat-bean guanidine, is obtained by separation of the valid target. Pharmacodynamical experiments prove that: the compound has sedative-hypnotic function, and can be used as a pharmaceutical and chemical raw material and be prepared into sedative-hypnotic preparation.

The invention relates to an anesthesia analgesia drug composition. The drug composition comprises a compound drug composition which can serve as a sedative hypnotic drug and contains rRemimazolam, derivatives of rRemimazolam and a narcotics analgesic.

The invention discloses a preparation method of isaria cicadae miq rice wine, glutinous rice as a main fermentation substrate is added with isaria cicadae miq powder and sweet wine yeast for collaborative frequency sweep ultrasonic fermentation for preparation of the isaria cicadae miq rice wine. The isaria cicadae miq rice wine can realize the effective extraction of sedative hypnotic components of isaria cicadae miq, has very good sedative and hypnotic effect, is stronger than the pure isaria cicadae miq water extract, after 5 times of dilution, still has 40-63% DPPH (1,1-diphenyl-2-picryl-hydrazyl) removal rate, has strong free radical scavenging effect, plays the anti-aging and disease prevention roles to a certain extent, and has the important meaning to improve the added value of the isaria cicadae miq.

The invention relates to a sedative-hypnotic preparation, a compound preparation, a preparation method and a pharmaceutical composition thereof. The compound preparation of the sedative-hypnotic preparation includes zopiclone or eszopiclone and a pharmaceutically acceptable auxiliary material which includes a stabilizing agent with a dosage being, by mass, 0.1%-10% of the zopiclone or the eszopiclone. The stabilizing agent is one or more of a pharmaceutically acceptable organic acid salt, a pharmaceutically acceptable organic acid buffer pair and a pharmaceutical acceptable anti-oxidant. The pharmaceutical composition of the sedative-hypnotic preparation forms a compound preparation pharmaceutical composition with other pharmaceutical active substances. The preparation method of the sedative-hypnotic preparation or the compound preparation includes carrying out a wet granulation process to the pharmaceutical composition of the sedative-hypnotic preparation or the compound preparation pharmaceutical composition. The sedative-hypnotic preparation or the compound preparation is good in stability and is excellent in dissolution rate and content uniformity. Quality of the preparations can be ensured and the preparations are suitable for industrial production.

An orally disintegrating tablet of sedative-hypnotic medicine and a preparation method for the same are disclosed. The invention relates to an orally disintegrating tablet of sedative-hypnotic medicine as well as a prescription and a process for preparing the orally disintegrating tablet of sedative-hypnotic medicine by a freeze-drying method. The orally disintegrating tablet of sedative-hypnotic medicine disclosed by the invention is prepared from main medicines and pharmaceutical excipients, without the need of water while being taken, capable of being rapidly disintegrated in mouth, and suitable for the medication of the patients with difficulty in swallowing, such as the old and children; simultaneously, the orally disintegrating tablet of sedative-hypnotic medicine is suitable for the medication in a condition that water source is not easy to obtain during travelling; moreover, the orally disintegrating tablet of sedative-hypnotic medicine can avoid the influence on sleep due to micturition desire because of no need of water while being taken, thus exerting curative effect better; and the orally disintegrating tablet of sedative-hypnotic medicine disclosed by the invention has better compliance and therapeutic effect in the case that the patients with neurological disease are passive or incoordinate and for the old patients with insomnia compared with other forms, and can obviously reduce the side effects of the sedative-hypnotic medicine. Additionally, the invention further relates to a preparation method for an orally disintegrating tablet of sedative-hypnotic medicine.

The present invention discloses a kind of tranquilizing and soporific compound composition of common jujube seed oil and arborvitae seed oil in the optimal ratio of 1 to 1. The common jujube seed oil and the arborvitae seed oil have synergistic central inhibition, so that the composition has both tranquilizing and soporific effects.

The invention belongs to the technical field of medicines and discloses novel application of pepper extractives in sedative-hypnotic. The pepper extractives use fruits or seeds of pepper plants as raw materials, and by means of a method of carbon dioxide supercritical fluid extraction or water extraction or ethanol extraction, the pepper extractives are obtained. By means of analysis and experimental verification of righting reflex experiments of mice and sleep time phase of rabbits, the pepper extractives have a good function of sedative-hypnotic, can be used in the development of sedative hypnotic Chinese medicines and natural medicines, and can also be used in the development of the health foods with effects of promoting sleep.

The invention discloses application of longitudinal stripe xylaria. The application is characterized in that sporocarp or alcohol extract of the longitudinal stripe xylaria can be applied to preparing a composition with a sedative effect, a composition with a hypnotic effect and a composition used for treating insomnia or anxiety; the compositions are medicine compositions or food compositions or health-care product compositions. The sporocarp of the longitudinal stripe xylaria is obtained through artificial culture, and the alcohol extract of the longitudinal stripe xylaria is obtained through extraction and concentration. The sporocarp or the alcohol extract of the longitudinal stripe xylaria has the remarkable sedative-hypnotic effect, is a natural active material for researching and developing novel health-care food and new medicine with the sedative-hypnotic effect, can be used for treating nervous system diseases such as insomnia or anxiety or convulsions, and is good in effect.